目的：探讨雷珠单抗和康柏西普治疗湿性年龄相关性黄斑变性(ARMD)的疗效。

方法：本文为回顾性研究。选取2014-02/2016-03于我院眼科就诊的湿性ARMD患者78例78眼，按照治疗方式不同分为两组，A组给予雷珠单抗治疗(39例39眼)，B组给予康柏西普治疗(39例39眼)。治疗后随访3mo，观察两组患者裸眼视力、黄斑中心凹视网膜厚度、脉络膜新生血管(CNV)渗漏及并发症等情况。

结果：治疗后1wk，1、3mo，A组患者裸眼视力均优于B组，差异有统计学意义(t=14.05、12.71、18.27，均P<0.05)； A组患者黄斑中心凹视网膜厚度均薄于B组，差异有统计学意义(t=13.04， 12.17， 18.19，均P<0.05)。治疗后1、3mo，两组患者治疗总有效率比较，差异无统计学意义(χ²=1.076、0.253，均P>0.05)。

结论：雷珠单抗和康柏西普治疗湿性ARMD的CNV渗漏疗效相当，均未出现严重并发症，但雷珠单抗对视力与黄斑中心凹视网膜厚度的改善情况稍好。

METHODS: Totally 78 cases(78 eyes)of wet age-related macular degeneration treated in our hospital from February 2014 to March 2016 were selected and divided into Group A and Group B, each with 39 cases(39 eyes). Patients in two groups were given ranibizumab and conbercept respectively, and were followed up for 12mo. The various data including visual acuity, the macular foveal retinal thickness, choroidal neovascularization(CNV)leakage and complications were compares between two groups.

RESULTS: At 1wk, 1 and 3mo after treatment, the uncorrected vision of Group A was higher than that of Group B, the difference was statistical significance(t=14.05, 12.71, 18.27; P<0.05). The macular foveal retinal thickness at different time points in Group A was thinner than that of Group B, the difference held statistical meaning(t=13.04, 12.17, 18.19; P<0.05). Two groups' total efficiency at 1 and 3mo after operation had no statistical points(χ²=1.076, 0.253; P>0.05).

CONCLUSION: The ranibizumab and conbercept shows identical effect in treating CNV leakage of patients wet age-related macular degeneration without any serious complications occurred, but the comparison of the two shows that the improvements of visual acuity and macular foveal retinal thickness are better in ranibizumab treatment than in conbercept treatment.